Graft versus host disease following liver transplantation: A case report

Graft versus host disease (GVHD) is an uncommon complication following liver transplantation. In the present case report, a 53-year-old male hepatitis B virus carrier was diagnosed with primary liver cancer with post-hepatitis cirrhosis. Preoperative cytomegalovirus (CMV), Epstein-Barr virus, coxsackievirus, herpes simplex virus and autoimmune antibody series were negative. Preoperative human leukocyte antigen type was also negative. Following classic orthotropic liver transplantation, postoperative treatment included immunosuppression therapy, infection protection, anti-human immunodeficiency virus therapy and CMV infection protection therapy. Chemotherapy was initiated at day 16 following surgery. At day 26 following the transplantation, the patient developed a fever of unknown cause, and a scattered red rash was observed behind the left ear and on the neck. The patient presented with a fever of unknown cause, rash, symptoms of the digestive tract, leukocytopenia and pancytopenia. A diagnosis of GVHD was confirmed following a skin biopsy. Symptomatic therapies, including antivirals, anti-anaphylaxis drugs and steroids were administered. However, the patient succumbed to infection, acute respiratory distress syndrome and multiple organ failure at day 46 following surgery. Therefore, an effective therapeutic strategy for the treatment of GVHD following liver transplantation is yet to be established, and further research is required prior to such a regimen being developed.

[1]  R. Storb,et al.  Prevention of graft-vs.-host disease , 2012, Expert opinion on pharmacotherapy.

[2]  G. Garas,et al.  Acute graft‐versus‐host disease after liver transplant: Novel use of etanercept and the role of tumor necrosis factor α inhibitors , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[3]  A. Palkova,et al.  Antibody to the dendritic cell surface activation antigen CD83 prevents acute graft-versus-host disease , 2009, The Journal of experimental medicine.

[4]  F. Dieli,et al.  Analysis of Memory and Effector CD8+ T Cell Subsets in Chronic Graft-versus-Host Disease , 2009, International journal of immunopathology and pharmacology.

[5]  G. Behre,et al.  Rituximab reduces the incidence of acute graft-versus-host disease. , 2009, Blood.

[6]  B. Bierer,et al.  Ex Vivo Rapamycin Generates Donor Th2 Cells That Potently Inhibit Graft-versus-Host Disease and Graft-versus-Tumor Effects via an IL-4-Dependent Mechanism1 , 2005, The Journal of Immunology.

[7]  R. Storb,et al.  Duration of immunosuppressive treatment for chronic graft-versus-host disease. , 2004, Blood.

[8]  E. Lanino,et al.  Mycophenolate mofetil (MMF) as therapy for refractory chronic GVHD (cGVHD) in children receiving bone marrow transplantation , 2000, Bone Marrow Transplantation.

[9]  A. Nademanee,et al.  Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. , 1998, Blood.

[10]  E D Thomas,et al.  1994 Consensus Conference on Acute GVHD Grading. , 1995, Bone marrow transplantation.